Biotinylated Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein
Catalog No: KRASG12V-HB009
- Species
- Human
- Expression System
- E. coli
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein is expressed from E.coli with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305 (HLA-A*03:01), Ile21-Met119 (B2M) and VVVGAVGVGK peptide (accession: NP_002107.3(HLA-A*03:01) & P61769(B2M) &VVVGAVGVGK).
Product Details
- Molecular Aliases
- MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
- Protein Length
- Gly25-Thr305
- Expression System
- E. coli
- Theoretical Molecular Weight
- The protein has a predicted MW of 35.26 kDa (HLA-A*03:01) and 11.9 kDa (B2M) same as Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Supplied as 0.22 μm filtered solution in 20mM Tris, 200mM NaCl (pH 8.0).
- State
- Liquid
- Storage Conditions
- Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Data Display
Biotinylated Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer is greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer, His Avi tag at 2μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Antibody, hFc Tag with the EC50 of 5.4ng/ml determined by ELISA. (QC Test)
Background
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
References
- (1) Wu HZ, Xiao JQ, Xiao SS, Cheng Y. KRAS: A Promising Therapeutic Target for Cancer Treatment. Curr Top Med Chem. 2019;19(23):2081-2097. doi: 10.2174/1568026619666190905164144. PMID: 31486755.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.